PDE12 in type 1 diabetes

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

PDE12 in type 1 diabetes. / Tekin, Hasim; Josefsen, Knud; Krogvold, Lars; Dahl-Jørgensen, Knut; Gerling, Ivan; Pociot, Flemming; Buschard, Karsten.

I: Scientific Reports, Bind 12, 18149, 2022.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Tekin, H, Josefsen, K, Krogvold, L, Dahl-Jørgensen, K, Gerling, I, Pociot, F & Buschard, K 2022, 'PDE12 in type 1 diabetes', Scientific Reports, bind 12, 18149. https://doi.org/10.1038/s41598-022-22890-x

APA

Tekin, H., Josefsen, K., Krogvold, L., Dahl-Jørgensen, K., Gerling, I., Pociot, F., & Buschard, K. (2022). PDE12 in type 1 diabetes. Scientific Reports, 12, [18149]. https://doi.org/10.1038/s41598-022-22890-x

Vancouver

Tekin H, Josefsen K, Krogvold L, Dahl-Jørgensen K, Gerling I, Pociot F o.a. PDE12 in type 1 diabetes. Scientific Reports. 2022;12. 18149. https://doi.org/10.1038/s41598-022-22890-x

Author

Tekin, Hasim ; Josefsen, Knud ; Krogvold, Lars ; Dahl-Jørgensen, Knut ; Gerling, Ivan ; Pociot, Flemming ; Buschard, Karsten. / PDE12 in type 1 diabetes. I: Scientific Reports. 2022 ; Bind 12.

Bibtex

@article{a9bc75722bdb4171908fa42fd9c40add,

title = "PDE12 in type 1 diabetes",

abstract = "Type 1 diabetes (T1D) incidence is increased after COVID-19 infection in children under 18 years of age. Interferon-α-activated oligoadenylate synthetase and downstream RNAseL activation degrade pathogen RNA, but can also damage host RNA when RNAseL activity is poorly regulated. One such regulator is PDE12 which degrades 2′-5′ oligoadenylate units, thereby decreasing RNAseL activity. We analyzed PDE12 expression in islets from non-diabetic donors, individuals with newly (median disease duration 35 days) and recently (5 years) diagnosed T1D, and individuals with type 2 diabetes (T2D). We also analyzed PDE12 single-nucleotide polymorphisms (SNPs) relative to T1D incidence. PDE12 expression was decreased in individuals with recently diagnosed T1D, in three of five individuals with newly diagnosed T1D, but not in individuals with T2D. Two rare PDE12 SNPs were found to have odds ratios of 1.80 and 1.74 for T1D development. We discuss whether decreased PDE12 expression after COVID-19 infection might be part of the up to 2.5-fold increase in T1D incidence.",

author = "Hasim Tekin and Knud Josefsen and Lars Krogvold and Knut Dahl-J{\o}rgensen and Ivan Gerling and Flemming Pociot and Karsten Buschard",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

doi = "10.1038/s41598-022-22890-x",

language = "English",

volume = "12",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "nature publishing group",

}

RIS

TY - JOUR

T1 - PDE12 in type 1 diabetes

AU - Tekin, Hasim

AU - Josefsen, Knud

AU - Krogvold, Lars

AU - Dahl-Jørgensen, Knut

AU - Gerling, Ivan

AU - Pociot, Flemming

AU - Buschard, Karsten

PY - 2022

Y1 - 2022

N2 - Type 1 diabetes (T1D) incidence is increased after COVID-19 infection in children under 18 years of age. Interferon-α-activated oligoadenylate synthetase and downstream RNAseL activation degrade pathogen RNA, but can also damage host RNA when RNAseL activity is poorly regulated. One such regulator is PDE12 which degrades 2′-5′ oligoadenylate units, thereby decreasing RNAseL activity. We analyzed PDE12 expression in islets from non-diabetic donors, individuals with newly (median disease duration 35 days) and recently (5 years) diagnosed T1D, and individuals with type 2 diabetes (T2D). We also analyzed PDE12 single-nucleotide polymorphisms (SNPs) relative to T1D incidence. PDE12 expression was decreased in individuals with recently diagnosed T1D, in three of five individuals with newly diagnosed T1D, but not in individuals with T2D. Two rare PDE12 SNPs were found to have odds ratios of 1.80 and 1.74 for T1D development. We discuss whether decreased PDE12 expression after COVID-19 infection might be part of the up to 2.5-fold increase in T1D incidence.

AB - Type 1 diabetes (T1D) incidence is increased after COVID-19 infection in children under 18 years of age. Interferon-α-activated oligoadenylate synthetase and downstream RNAseL activation degrade pathogen RNA, but can also damage host RNA when RNAseL activity is poorly regulated. One such regulator is PDE12 which degrades 2′-5′ oligoadenylate units, thereby decreasing RNAseL activity. We analyzed PDE12 expression in islets from non-diabetic donors, individuals with newly (median disease duration 35 days) and recently (5 years) diagnosed T1D, and individuals with type 2 diabetes (T2D). We also analyzed PDE12 single-nucleotide polymorphisms (SNPs) relative to T1D incidence. PDE12 expression was decreased in individuals with recently diagnosed T1D, in three of five individuals with newly diagnosed T1D, but not in individuals with T2D. Two rare PDE12 SNPs were found to have odds ratios of 1.80 and 1.74 for T1D development. We discuss whether decreased PDE12 expression after COVID-19 infection might be part of the up to 2.5-fold increase in T1D incidence.

U2 - 10.1038/s41598-022-22890-x

DO - 10.1038/s41598-022-22890-x

M3 - Journal article

C2 - 36307540

AN - SCOPUS:85140877490

VL - 12

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 18149

ER -

ID: 344978152